Study: Bimekizumab Achieves Complete Psoriasis Clearance in Most Patients at 2 Years
Key Takeaways
A 2-year Canadian real-world study found that 71.1% of patients with plaque psoriasis treated with bimekizumab achieved complete skin clearance (PASI 100) at week 104.
Treatment persistence remained high at 88.8% after 2 years, with comparable observed clearance rates among biologic-naïve and biologic-experienced patients.
Oral candidiasis was the most frequently reported treatment-related adverse event (8.6%).
A 2-year multicenter real-world study published in the Journal of the American Academy of Dermatology (JAAD) found that 71.1% of adults with plaque psoriasis treated with bimekizumab achieved complete skin clearance, with treatment persistence approaching 89% at week 104.
The retrospective study evaluated 152 adults receiving standard-dose bimekizumab, an interleukin-17A and interleukin-17F inhibitor, across four Canadian institutions. Patients had a mean age of 48.3 years, and 61.2% were male. Investigators assessed effectiveness, safety, and treatment persistence over 104 ± 8 weeks.
Sustained Psoriasis Clearance and Treatment Persistence at 2 Years
Using nonresponder imputation, researchers reported that 81.6% of patients achieved an Investigator Global Assessment (IGA) score of 0 or 1 at 2 years. PASI 75, PASI 90, and PASI 100 responses were achieved by 77.0%, 75.7%, and 71.1% of patients, respectively. Additionally, 84.2% achieved body surface area involvement of 1% or less. Treatment persistence was 99.3% at week 16, 94.7% at week 52, and 88.8% at week 104. Although observed response rates were comparable between biologic-naïve and biologic-experienced patients, biologic-naïve patients achieved IGA 0/1 (hazard ratio [HR], 1.57; P = 0.016) and PASI 90 (HR, 1.67; P = 0.008) more rapidly.
Treatment-related adverse events were reported in 13.8% of patients, most commonly oral candidiasis (8.6%). Seventeen patients (11.2%) discontinued treatment, primarily because of insufficient efficacy. No serious infections or malignancies were observed during more than 284 patient-years of safety follow-up.
Limitations included the retrospective design, modest sample size, and potential selection bias associated with specialized tertiary centers.
Source
Waked J, et al. J Am Acad Dermatol. October 2026. Doi:10.1016/j.jaad.2026.10.049